Fieldays spotlight: Christchurch start-up's sheepskin collagen powder
A Christchurch start-up is extracting proteins from sheepskin and processed them into a collagen powder for health and wellness products.
Photo:
RNZ / Kate Green
A Christchurch biotechnology start-up is using sheepskins diverted from waste to create a world-first collagen powder for the booming health and wellness market.
The company, Tertiary Extracts Ōtautahi, extracted protein from sheepskin to create its branded bioactive protein Ovitage that was then processed into a collagen powder and marketed in various health products.
The company was up for an early-stage innovation award at this week's Fieldays event in Waikato against more than 30 others.
Founder and chief science officer Dr Rob Kelly said the company developed the technology to isolate and extract valuable protein ingredients from the sheepskin and make it into the unique collagen powder.
"The composition of our signature protein, which is ovitage collagen, is quite different to any collagen that's been made before," Kelly said.
"The amino acid profile is really quite different. People haven't seen this before and the particular amino acids present leads to significant health benefits in areas that are in particular demand in New Zealand and overseas as well."
Kelly, no stranger to research and development within the sheep sector, had links to the Wool Research Organisation of New Zealand (WRONZ), Keratec and Keraplast Technologies.
He said Tertiary Extracts Ōtautahi sourced the sheepskin material from producers who only used sheep from New Zealand.
"We have an abundance of sheepskin materials, between 6-7 million sheepskins are produced each year, and they currently don't have good uses," Kelly said.
He said most skins were by-products of the red meat sector that were low value and cost producers to dispose of.
"Sheepskin is an issue for the sector as a whole, and so we're really trying to present a whole-of-industry solution," he said.
Tertiary Extracts Ōtautahi's head of research and development Dr Alisa Roddick Lanzilotta and chief scientist officer Dr Rob Kelly are behind the process to extract valuable proteins from sheepskin to create a collagen powder.
Photo:
SUPPLIED/Tertiary Extracts Ōtautahi
Kelly said its Ovitage product targeted the health and wellness segment domestically in New Zealand and via export into the United States.
He said bovine and marine made up the bulk of the $15 billion global market for collagen, and demand was continuing to grow.
"We've put a lot of investment and science and research into the novel process that we've developed and we're really excited by the market opportunities and the export opportunities," Kelly said.
Tertiary Extracts Otautahi will be in the Innovation Hub at Mystery Creek this week - ahead of the Innovation Awards ceremony on Thursday, and its product Everee Women could also be found in the health and wellbeing hub.
On Friday, Kelly will also feature in the event's Tent Talks, on New Zealand's ability to turn scientific breakthroughs into globally competitive export businesses.
The company was also a finalist for a technology innovation award at the Primary Industries NZ Awards in two week's time.
Sign up for Ngā Pitopito Kōrero
,
a daily newsletter curated by our editors and delivered straight to your inbox every weekday.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
RNZ News
an hour ago
- RNZ News
Home loan rates fall again
Photo: AFP Westpac is cutting some of its home loan rates and slightly increasing one other. The bank said it would reduce its one-year rate to 4.89 percent, a drop of six basis points. Its three-year rate will lift by four basis points to 4.99 percent. The six-month rate drops by 20 basis points to 5.29 percent. The bank's general manager of product, sustainability and marketing, Sarah Hearn, said the rates would be available on Friday. The one-year rate is the joint lowest in the market, tied with Kiwibank. ANZ, ASB and BNZ are offering 4.89 percent for 18 months, while Westpac is still offering 4.95 percent for that term. Swap rates have fallen significantly from the start of the year, although they have started to lift a little more recently, on expectations that the Reserve Bank might be near the bottom of its official cash rate cutting cycle. BNZ chief economist Mike Jones said the fact that the decision this time went to a vote was one factor that illustrated that. One member of the monetary policy committee voted against the decision to cut the official cash rate at the most recent update. "The fact you had one committee member wanting to pause for a meeting - you've got to add that to some of the comments from [committee] members at or after the decision around where we might be in relation to the cycle as a whole. "It does tend to guide us to we're probably on the home stretch, whether it's one more, two more or even three more cuts, the messaging there tends to suggest we've had some big cuts to date and based on everything we know now we're getting towards the end - although there's always that optionality to respond to changing conditions and conditions are changing really rapidly at the moment." He said BNZ's official forecast was still for two more cuts to an OCR low of 2.75 percent. "When we look at the language from the bank combined with some of the data that has come in a bit firmer than we might have expected, that lead us to the risk of maybe just one but we still expect two. If that's right that means in terms of market interest rates, it's just the floating rates and the shorter term rates that have that much further to fall from here. We might getting close to or at the bottom for some of those longer term interest rates."
RNZ News
an hour ago
- RNZ News
Pharmac considers extension to free meningoccocal B vaccination programme
An estimated 100,000 pre-schoolers are still unprotected. Photo: Pharmac says it's exploring ways to extend a free meningoccocal B vaccine programme, with an estimated 100,000 eligible pre-schoolers still not protected. Meningitis prevention advocates have pressured health officials to continue the campaign, which is due to end on 31 August. Pharmac pharmaceuticals director Geraldine MacGibbon said Pharmac funds the meningococcal B vaccine for all children under the age of one. "In March 2023, Pharmac funded a catch-up programme for children under the age of five to better protect young New Zealanders from meningococcal B. "We understand that people are keen to see the catch-up period extended and we are actively exploring options for this." "We will keep interested groups, including the Meningitis Foundation, informed about any updates," MacGibbon said. According to the Meningitis Foundation Aotearoa New Zealand, meningococcal bacteria can cause meningococcal meningitis - inflammation of the meninges, the membrane lining of the brain and spinal cord - and/or septicaemia (blood poisoning). Foundation chair Gerard Rushton said the meningococcal B vaccination programme was initiated after a submission the foundation made to Parliament and an application to Pharmac. He said more than 400,000 doses were given out in the first 12 months of the campaign. "We're calling on Health New Zealand and the government to actually continue this programme, because we know it works. We know it will save lives. "We know it's going to take pressure off the already-stretched health system. "What we're saying is this campaign has been very successful and it's been proven that people want it, but there's still 100,000 of our tamariki that haven't been protected, so we're calling them to keep this programme going. "We're really concerned that this large sector of our community are going to miss out. The vaccination rates for our young are still far too low, but we need them to extend this programme, because we need to protect those 100,000 of our children who are still unvaccinated." A Health New Zealand spokesperson said it was are "responsible for the implementation of the programme". "Pharmac funds the meningococcal B catch-up programme and set the timeframe from 1 March 2023 to 31 August 2025." A Health New Zealand spokesperson said, as of 9 June 2025, 84 percent of eligible children under 15 months had at least one dose of the meningococcal B vaccine. "Whānau can access the meningococcal B vaccines from a range of places, including general practice, hauora Māori and Pacific providers, with many Wellchild Tamariki Ora Services, including Whānau Āwhina Plunket, offering immunisations. "There are also more than 122 pharmacies now offering the vaccine for children aged from three years. "The meningococcal B vaccination is a part of the national immunisation schedule. "As a part of the Government's Health Target, we are focused on lifting childhood immunisation rates and we are making good progress towards this goal," said the spokesperson. Meningitis Foundation Aotearoa New Zealand chair Gerard Rushton said his organisation didn't see a reason for the catch-up programme to be discontinued. "Māori and Pasifika are 4-5 times more likely to catch meningitis than the European population, so they are a higher risk at the moment. We struggle to understand why there's a vaccination programme at the moment that actually discriminates against them. "The full vaccination programme was that the babies are free, there was a catch-up programme for 13-month to 5-year-olds, and that first-year students in boarding schools, halls of residence, barracks or prisons could get it free." "We feel that discriminates against the biggest at-risk group we've got, which is our Māori and Pasifika, because they're under-represented at halls of residence and boarding schools," he said.
RNZ News
2 hours ago
- RNZ News
Pharmac consider extension to free vaccination programme
An estimated 100,000 pre-schoolers are still unprotected. Photo: SERGII IAREMENKO/SCIENCE PHOTO L Pharmac says it's exploring ways to extend a free meningoccocal B vaccine programme, with an estimated 100,000 eligible pre-schoolers still not protected. Meningitis prevention advocates have pressured health officials to continue the campaign, which is due to end on 31 August. Pharmac pharmaceuticals director Geraldine MacGibbon said Pharmac funds the meningococcal B vaccine for all children under the age of one. "In March 2023, Pharmac funded a catch-up programme for children under the age of five to better protect young New Zealanders from meningococcal B. "We understand that people are keen to see the catch-up period extended and we are actively exploring options for this." "We will keep interested groups, including the Meningitis Foundation, informed about any updates," MacGibbon said. According to the Meningitis Foundation Aotearoa New Zealand, meningococcal bacteria can cause meningococcal meningitis - inflammation of the meninges, the membrane lining of the brain and spinal cord - and/or septicaemia (blood poisoning). Foundation chair Gerard Rushton said the meningococcal B vaccination programme was initiated after a submission the foundation made to Parliament and an application to Pharmac. He said more than 400,000 doses were given out in the first 12 months of the campaign. "We're calling on Health New Zealand and the government to actually continue this programme, because we know it works. We know it will save lives. "We know it's going to take pressure off the already-stretched health system. "What we're saying is this campaign has been very successful and it's been proven that people want it, but there's still 100,000 of our tamariki that haven't been protected, so we're calling them to keep this programme going. "We're really concerned that this large sector of our community are going to miss out. The vaccination rates for our young are still far too low, but we need them to extend this programme, because we need to protect those 100,000 of our children who are still unvaccinated." A Health New Zealand spokesperson said it was are "responsible for the implementation of the programme". "Pharmac funds the meningococcal B catch-up programme and set the timeframe from 1 March 2023 to 31 August 2025." A Health New Zealand spokesperson said, as of 9 June 2025, 84 percent of eligible children under 15 months had at least one dose of the meningococcal B vaccine. "Whānau can access the meningococcal B vaccines from a range of places, including general practice, hauora Māori and Pacific providers, with many Wellchild Tamariki Ora Services, including Whānau Āwhina Plunket, offering immunisations. "There are also more than 122 pharmacies now offering the vaccine for children aged from three years. "The meningococcal B vaccination is a part of the national immunisation schedule. "As a part of the Government's Health Target, we are focused on lifting childhood immunisation rates and we are making good progress towards this goal," said the spokesperson. Meningitis Foundation Aotearoa New Zealand chair Gerard Rushton said his organisation didn't see a reason for the catch-up programme to be discontinued. "Māori and Pasifika are 4-5 times more likely to catch meningitis than the European population, so they are a higher risk at the moment. We struggle to understand why there's a vaccination programme at the moment that actually discriminates against them. "The full vaccination programme was that the babies are free, there was a catch-up programme for 13-month to 5-year-olds, and that first-year students in boarding schools, halls of residence, barracks or prisons could get it free." "We feel that discriminates against the biggest at-risk group we've got, which is our Māori and Pasifika, because they're under-represented at halls of residence and boarding schools," he said.
